Posts

What Cancer Patients Need To Know About “Biosimilars”

In 1984, Congress passed what is commonly referred to as Hatch-Waxman, a bill intended to lower the cost of prescription drugs by making generic versions available after an exclusivity period. However, one group of medicines, called biologics, was excluded from the bill. Many of the medicines used to treat colon cancer, such as Avastin and Erbitux, are biologics and so there are not lower cost versions available; however, that may be about to change.

Read more